Skip to main content

PT-141 (Bremelanotide)

Also known as: Bremelanotide, Vyleesi

By the Peptide Dossier Editorial TeamUpdated How we source

Bremelanotide is the active molecule in Vyleesi, approved for acquired, generalized HSDD in premenopausal women. RECONNECT showed modest improvements in desire and related distress. Research-market PT-141 is not the approved product, and early male studies have a different evidentiary scope.

Quick Facts

Class:MC4R agonist
Evidence context:Phase 3 HSDD desire/distress benefit is modest and population specific; early male studies do not establish approval or broad gray-market efficacy.
Product context:Vyleesi is FDA-approved for acquired generalized HSDD in premenopausal women; research-market and compounded PT-141 are not approved finished products.

What is bremelanotide?

Bremelanotide is a synthetic cyclic seven-amino-acid melanocortin agonist, originally developed as PT-141. Vyleesi is its prescription subcutaneous autoinjector, used in the thigh or abdomen for a defined form of low sexual desire in premenopausal women. Online “PT-141,” compounded versions and research vials or nasal sprays are not the FDA-approved finished product. Related Melanotan II and alpha-MSH are not interchangeable identity synonyms.

The history of bremelanotide

The development path began with University of Arizona research on skin-darkening melanocortins. Sexual arousal observed during Melanotan II testing prompted study of that pathway for sexual dysfunction. Palatin Technologies developed PT-141 first in erectile-function research and later in women’s low-desire trials; FDA approved Vyleesi in 2019. Afamelanotide, another relative from tanning research, followed a separate path for a rare photosensitivity disorder.

Sources: [1]

How does bremelanotide work?

Bremelanotide activates central melanocortin receptors, notably MC4R and also MC1R, in pathways associated with sexual desire. The exact therapeutic HSDD mechanism is not established by the label. This differs from sildenafil or tadalafil, which inhibit PDE5/cGMP breakdown in penile vascular smooth muscle to support blood flow in the presence of sexual stimulation.

A 2022 crossover fMRI study in 31 premenopausal women with HSDD tested 1.75 mg subcutaneously against placebo. Erotic-stimulus responses increased in cerebellar and supplementary motor areas (Z = 2.3, P < 0.05), secondary somatosensory cortex activity decreased, and amygdala–insula connectivity increased (F(1,30) = 5.55, P = 0.025). These imaging findings suggest altered erotic imagery, self-consciousness and sensitivity to stimuli; they do not establish every proposed causal mechanism.

Sources: [3], [7], [8], [12]

Is it FDA-approved?

FDA approved Vyleesi in June 2019 for acquired, generalized HSDD in premenopausal women. “Acquired” means developing after previous normal function; “generalized” means not restricted to one partner or situation. It was the second approved HSDD medicine after flibanserin (Addyi, 2015) and the first approved for on-demand use. Approval does not cover men, postmenopausal women or general performance enhancement. Research-market PT-141 was not among the peptides favorably reviewed at the 2026 compounding meetings.

Sources: [2], [10], [11]

What is bremelanotide prescribed for?

The indication concerns persistent low desire causing marked distress or interpersonal difficulty, not better explained by another medical/psychiatric condition, relationship issue or medication. A clinician determines suitability and monitors response. The approved label excludes uncontrolled hypertension and known cardiovascular disease, and recommends discontinuation when improvement is absent.

What are the side effects?

Nausea is common and sometimes requires anti-nausea treatment; flushing, headache, vomiting and injection reactions also occur. Each dose can transiently raise blood pressure and lower heart rate. Repeated use may cause focal skin or gum hyperpigmentation, with greater risk with frequent dosing and darker skin.

A 2016 twelve-week dose-finding RCT in 327 premenopausal women studied 0.75–1.75 mg subcutaneously and identified nausea, flushing and headache. A 52-week open-label extension reported no new safety signal, but a 2025 narrative review’s concerns about limited efficacy and potential adverse effects still warrant clinical caution. The label also addresses oral-drug interactions, including naltrexone. Pregnancy use is not recommended, and effective contraception is advised.

Sources: [15]

What about "PT-141" sold online?

Research-chemical sellers often market PT-141 for both sexes and general libido, sometimes as vials or nasal sprays labeled “not for human use.” Their identity, actual dose, purity and sterility are not assured, and contamination or misdosing risks are distinct from a trial using a controlled formulation.

Compounded bremelanotide is also not FDA-approved; its quality depends on the particular preparation and pharmacy. Blood-pressure and heart-rate effects make the absence of screening particularly consequential. Approval, quality control and evidence for Vyleesi cannot be transferred automatically to these other products.

What does the research show?

The two 24-week RECONNECT randomized placebo-controlled trials enrolled 1,267 premenopausal women with HSDD, with 1,202 in the modified intention-to-treat efficacy population. On-demand 1.75 mg subcutaneous bremelanotide improved the FSFI desire score by 0.35 points more than placebo (P < 0.001; study 301 +0.30, study 302 +0.42) and reduced FSDS-DAO item-13 distress by 0.33 points more (P < 0.001). A 2024 independent analysis judged effects statistically modest and challenged the outcome measures’ validity in HSDD.

The extension enrolled 684 women, of whom 272 completed the additional 52 weeks. Among prior bremelanotide recipients, desire increased 1.25–1.30 points from baseline and distress decreased 1.4–1.7 points, without a new safety signal. Attrition, selection and lack of placebo limit causal interpretation. These findings do not establish improvement in every sexual complaint or controlled efficacy of gray-market products for general libido.

Sources: [4], [5], [6], [9]

Early male studies and approved-product instructions

A 2004 intranasal study in healthy men and men with ED responsive to sildenafil found significant RigiScan erectile response above 7 mg, with first erection around 30 minutes. Another 2004 program tested 0.3–10 mg subcutaneously in healthy men, with significant responses above 1.0 mg; 4 and 6 mg produced significant responses versus placebo in a crossover study of inadequate sildenafil responders. These are early-phase studies, not an approved male treatment or proof of a general libido effect.

A separate randomized crossover laboratory study in 19 men found greater measured erectile response with nasal PT-141 plus sildenafil than sildenafil alone. It does not establish routine long-term combination safety or sexual satisfaction in broader populations.

For the approved Vyleesi autoinjector, labeling specifies 1.75 mg under the skin at least 45 minutes before activity, no more than one dose per 24 hours; more than eight doses per month is not recommended. Stop after eight weeks without improvement. Those instructions do not establish a generic powder, nasal-spray or compounded regimen.

Sources: [13], [14]

References and further reading

This reference draws on Superpower reference 1, Superpower reference 2 and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .

  1. sciencedirect.comThe history of bremelanotideCited in: The history of bremelanotide
  2. palatin.comIs it FDA-approved?Cited in: Is it FDA-approved?
  3. accessdata.fda.govHow does bremelanotide work?Cited in: How does bremelanotide work?
  4. 10.1097/AOG.0000000000003500What does the research show?Cited in: What does the research show?
  5. 10.1080/00224499.2023.2175192What does the research show?Cited in: What does the research show?
  6. 10.1007/s40265-019-01187-wWhat does the research show?Cited in: What does the research show?
  7. dailymed.nlm.nih.govHow does bremelanotide work?Cited in: How does bremelanotide work?
  8. dailymed.nlm.nih.govHow does bremelanotide work?Cited in: How does bremelanotide work?
  9. 10.1097/AOG.0000000000003514What does the research show?Cited in: What does the research show?
  10. accessdata.fda.govIs it FDA-approved?Cited in: Is it FDA-approved?
  11. 10.1177/10600280241253273Is it FDA-approved?Cited in: Is it FDA-approved?
  12. 10.1172/JCI152341How does bremelanotide work?Cited in: How does bremelanotide work?
  13. 10.1038/sj.ijir.3901139Early male studies and approved-product instructionsCited in: Early male studies and approved-product instructions
  14. 10.1038/sj.ijir.3901200Early male studies and approved-product instructionsCited in: Early male studies and approved-product instructions
  15. 10.2217/whe-2016-0018What are the side effects?Cited in: What are the side effects?
  16. www.accessdata.fda.gov — additional reading
  17. dailymed.nlm.nih.gov — additional reading
  18. pubmed.ncbi.nlm.nih.gov — additional reading
  19. pubmed.ncbi.nlm.nih.gov — additional reading
  20. pubmed.ncbi.nlm.nih.gov — additional reading

Frequently Asked Questions About PT-141 (Bremelanotide)

No. Related melanocortin compounds should not be treated as interchangeable drug identities.

No. The small crossover combination study used a different formulation and measured laboratory erectile responses.

The approved product described here is a subcutaneous autoinjector; its instructions do not validate generic nasal products.

Bremelanotide acts through central melanocortin pathways associated with desire. Sildenafil and tadalafil support vascular blood flow through PDE5 inhibition and still require sexual stimulation. Different mechanisms do not establish interchangeable indications or a validated combination for everyone.

Across 1,267 randomized women with HSDD, 1.75 mg on demand over 24 weeks improved desire by 0.35 points more than placebo and reduced related distress by 0.33 points. Effects were statistically significant but modest; independent analysis questioned the outcome measures.

Premenopausal women with acquired, generalized HSDD meeting the product’s criteria. It is not approved for men, postmenopausal women or sexual-performance enhancement.

A 31-woman crossover study found altered responses to erotic stimuli and increased amygdala–insula connectivity after 1.75 mg subcutaneously. Imaging signals are research findings, not proof of every proposed mechanism or general libido benefit.

Early randomized laboratory studies found erectogenic responses with specific nasal or subcutaneous preparations, but no male Phase 3 program or FDA-approved male indication is established. Those exposures do not validate research-vendor products or a home protocol.

Nausea, flushing and headache are frequent trial findings; vomiting and injection reactions also occur. Blood-pressure/heart-rate effects, focal pigmentation, cardiovascular exclusions and product-specific interactions remain important even though the extension reported no new signal.

Related Peptides

Continue exploring PT-141 (Bremelanotide)

Search all related references →

Our library review is ongoing. Read how we evaluate evidence or report a correction.

Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.